Zoledronsäure Hikma

Zoledronic Acid Monohydrate is a bisphosphonate medication used to prevent bone complications in patients with bone metastases. It belongs to the class of drugs known as bisphosphonates and is administered intravenously. This formulation is manufactured by Hikma Farmacêutica (Portugal), S.A. and is available in the EU market.

Zoledronic Acid Monohydrate is primarily used to reduce bone pain and the risk of fractures in patients with bone metastases from solid tumors such as breast cancer, prostate cancer, or lung cancer. It may also be prescribed to manage hypercalcemia of malignancy, a condition where high calcium levels in the blood are caused by cancer. Additionally, it is sometimes used to treat osteoporosis and Paget's disease of bone.

This medication works by slowing down bone resorption, which helps maintain bone strength and reduce the risk of fractures. Patients may experience a reduction in bone pain over time as the medication takes effect. Some individuals report improved mobility and a general sense of well-being as their bone health stabilizes.

Zoledronic Acid Monohydrate should be handled with care, and healthcare professionals must ensure proper administration to minimize risks. Patients are advised to stay well-hydrated before and after treatment to reduce the risk of kidney issues. Regular dental check-ups are recommended, as this medication may increase the risk of jaw problems.

This medication may interact with other drugs that affect kidney function, such as diuretics or certain antibiotics. Caution is advised when combining it with medications that lower calcium levels in the blood. Alcohol and tobacco use may also impact bone health and should be discussed with a healthcare provider. Always inform your doctor about all medications and supplements you are taking.